Full Text View
Tabular View
No Study Results Posted
Related Studies
AMP as a Better Delivery System of Adenosine
This study has been suspended.
( In process of renewing IND for AMP )
Study NCT00179010   Information provided by Vanderbilt University
First Received: September 13, 2005   Last Updated: December 22, 2007   History of Changes

September 13, 2005
December 22, 2007
October 2003
January 2008   (final data collection date for primary outcome measure)
  • Interstitial adenosine levels [ Time Frame: Duration of ia infusion ] [ Designated as safety issue: No ]
  • Forearm blood flow [ Time Frame: Duration of ia infusion ] [ Designated as safety issue: No ]
  • Interstitial adenosine levels
  • Forearm blood flow
  • Heart rate
  • Blood pressure
Complete list of historical versions of study NCT00179010 on ClinicalTrials.gov Archive Site
 
Symptoms
 
AMP as a Better Delivery System of Adenosine
Use of AMP to Improve Tissue Delivery of Adenosine

Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore, very little of the adenosine we give by vein or in the artery actually reaches the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we will increase levels of adenosine in tissue. To see if this is true, we will give either adenosine or AMP into the forearm artery while we measure how much adenosine reaches the forearm tissue.

 
 
Interventional
Other, Non-Randomized, Single Blind (Subject), Active Control, Crossover Assignment, Efficacy Study
Ischemia
  • Drug: Adenosine
  • Drug: Adenosine Mono Phosphate (AMP)
  • Experimental: Intrarterial infusion of adenosine
  • Experimental: Intrarterial infusion of AMP
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Suspended
64
January 2008
January 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers
  • Age 18-65
  • Non smokers

Exclusion Criteria:

  • Smokers
  • Any chronic disease
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00179010
Italo Biaggioni, Vanderbilt University
030371
Vanderbilt University
 
Principal Investigator: Italo Biaggioni, M.D. Vanderbilt University
Vanderbilt University
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP